Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epigenetic agents in combined anticancer therapy

Z. Kejík, M. Jakubek, R. Kaplánek, J. Králová, I. Mikula, P. Martásek, V. Král,

. 2018 ; 10 (9) : 1113-1130. [pub] 20180420

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012714

In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012714
003      
CZ-PrNML
005      
20190411131912.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.4155/fmc-2017-0203 $2 doi
035    __
$a (PubMed)29676175
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kejík, Zdeněk $u First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic.
245    10
$a Epigenetic agents in combined anticancer therapy / $c Z. Kejík, M. Jakubek, R. Kaplánek, J. Králová, I. Mikula, P. Martásek, V. Král,
520    9_
$a In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a kombinovaná terapie $x metody $7 D003131
650    _2
$a metylace DNA $x účinky léků $7 D019175
650    _2
$a DNA modifikační methylasy $x farmakologie $7 D015254
650    _2
$a objevování léků $x metody $7 D055808
650    _2
$a epigeneze genetická $x účinky léků $7 D044127
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a histonacetyltransferasy $x antagonisté a inhibitory $7 D051548
650    _2
$a inhibitory histondeacetylas $x farmakologie $x terapeutické užití $7 D056572
650    _2
$a histondemethylasy $x antagonisté a inhibitory $7 D056466
650    _2
$a histonmethyltransferasy $x antagonisté a inhibitory $7 D000076983
650    _2
$a lidé $7 D006801
650    _2
$a nádory $x farmakoterapie $x genetika $x terapie $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Jakubek, Milan $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic. Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry & Technology, Technická 5, 166 28 Prague 6, Czech Republic.
700    1_
$a Kaplánek, Robert $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic. Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry & Technology, Technická 5, 166 28 Prague 6, Czech Republic.
700    1_
$a Králová, Jarmila $u First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic.
700    1_
$a Mikula, Ivan $u First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic.
700    1_
$a Martásek, Pavel $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic.
700    1_
$a Král, Vladimír $u First Faculty of Medicine, Charles University in Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic. BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic. Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry & Technology, Technická 5, 166 28 Prague 6, Czech Republic.
773    0_
$w MED00180228 $t Future medicinal chemistry $x 1756-8927 $g Roč. 10, č. 9 (2018), s. 1113-1130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29676175 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411131929 $b ABA008
999    __
$a ok $b bmc $g 1392024 $s 1051019
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 10 $c 9 $d 1113-1130 $e 20180420 $i 1756-8927 $m Future medicinal chemistry $n Future Med Chem $x MED00180228
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace